Autonomix Medical, Inc. (AMIX) Fair Value 2026

AMIX · Medical Devices ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.2 /10

32 fundamental signals · 2 models active

Value Trap Risk

WARN (53/100)

Quick Summary — As of 2026-08-27, Autonomix Medical, Inc. (AMIX) trades at $5.63, versus a $7.10 median fair value across its 2 active models — 26.1% above the current price. QOC: 4.2/10. Value Trap Risk: 53/100 (WARN). 2/13 models active.

Key Facts

Ticker
AMIX
Price
$5.63
Quality Score
4.2/10
Value Trap Risk
53/100
Models Active
2/13
Last Updated
Strength: Dynamic NAV suggests +104.4% upside with 53% confidence
Risk: Value Trap score of 53 suggests caution despite apparent undervaluation

Is Autonomix Medical, Inc. (AMIX) Undervalued or Overvalued in 2026?

According to CirclFi’s 2-model valuation engine, Autonomix Medical, Inc. (AMIX) appears undervalued as of : the median of 2 independent fair value estimates is $7.10, 26.1% above the current price of $5.63. Estimates range from $2.69 to $11.51. AMIX scores 4.2/10 on fundamental quality and 53/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.7% versus its own 13-model consensus, across 3,801 rated companies as of 2026-08-27. AMIX’s +26.1% gap is wider than that market norm, and the Medical Devices sector median is -43.5%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Autonomix Medical, Inc. Stock in 2026? →

What Fair Value Does Each Model Give AMIX?

2 Intrinsic Value Models vs. Current Price ($5.63)

Core Models (Unlocked)
Model Fair Value Upside
Asset-Based · High Conviction
 $11.51 +104.4%
Option-Based · Medium Conviction
 $2.69 -52.3%

All Models Active

All 2 models are displayed above.

What Is Autonomix Medical, Inc. (AMIX) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Autonomix Medical, Inc.'s intrinsic value is estimated at a median $7.10, showing conflicting signals at the current price of $5.63. While the median implied return is +26.1%, model disagreement is elevated with a gap of +156.7% between the most bullish and bearish estimates. The most optimistic model, Dynamic NAV, places fair value at $11.51 (+104.4%), while PWERM — the most conservative — estimates $2.69 (-52.3%). This +156.7% gap reflects genuine analytical uncertainty about Autonomix Medical, Inc.'s intrinsic worth.

What Do the Models Say About AMIX?

2 of 13 models are currently active for AMIX. Of these, 1 model suggests upside while 1 model suggests overvaluation. Taken together, their median fair value for AMIX is $7.10 — the figure CirclFi publishes as this stock's fair value. See which stocks rank higher →

How Does AMIX Rank in Medical Devices?

Among 157 Medical Devices stocks, AMIX ranks #142 by Quality of Company score. CirclFi's QOC score of 4.2/10 evaluates 32 fundamental signals. A score of 4.2 reflects mixed fundamentals.

See all Most Undervalued Medical Devices Stocks →

As a pharmaceutical industry, Autonomix Medical, Inc. operates in a sector where patent cliff exposure is a critical driver of valuation. Investors evaluating AMIX should weigh these sector-specific dynamics alongside our model-derived fair values.

Is AMIX a Value Trap?

CirclFi's Value Trap algorithm assigns AMIX a score of 53/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

2 of 13 models are active for Autonomix Medical, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Autonomix Medical, Inc.'s fundamental quality profile registers 4.2/10. This mixed score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

The gap between the most bullish and bearish model spans +156.7% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every AMIX valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across AMIX's 2 active models, average confidence is 42%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Autonomix Medical, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Medical Devices Stocks Should You Also Analyze?

11 related Medical Devices stocks with 13-model coverage

NVNOenVVeno Medical CorporationQOC 4.2NUMDNu-Med Plus, Inc.QOC 4.2POSCPositron CorporationQOC 4.3PFSAProfusa, Inc.QOC 4.1ADGMAdagio Medical Holdings, Inc.QOC 4.3MOBIMobia Medical, Inc.QOC 3.9BVSBioventus Inc.QOC 8.2NSYSNortech Systems IncorporatedQOC 6.6BMRABiomerica, Inc.QOC 5.7IRMDIRADIMED CORPORATIONQOC 9.8PODDInsulet CorporationQOC 9.6

Read investment analysis: NVNO · NUMD · POSC · PFSA · ADGM · MOBI · BVS · NSYS · BMRA · IRMD · PODD

Which Other Stocks Have a Similar Quality Score to AMIX?

7 companies across all industries closest to AMIX’s Quality of Company score of 4.2/10.

BBLGBone Biologics CorporationQOC 4.2SSTSystem1, Inc.QOC 4.2XELBXcel Brands, Inc.QOC 4.2HCWBHCW Biologics Inc.QOC 4.2SYRESpyre Therapeutics, Inc.QOC 4.2RVPHReviva Pharmaceuticals Holdings, Inc.QOC 4.2NVDANVIDIA CorporationQOC 10.0

Read investment analysis: BBLG · SST · XELB · HCWB · SYRE · RVPH · NVDA

Where Does AMIX Sit in CirclFi's Medical Devices Rankings?

AMIX is ranked against every other Medical Devices stock CirclFi covers in each of these screens.

See all Medical Devices stocks ranked →

What Else Do Investors Ask About Autonomix Medical, Inc.’s Valuation?

What is Autonomix Medical, Inc.'s intrinsic value in 2026?

CirclFi puts Autonomix Medical, Inc. (AMIX)'s intrinsic value at $7.10 — the median of 2 independent model estimates as of 2026-08-27, ranging from $2.69 to $11.51. The Quality of Company score is 4.2/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is AMIX overvalued or undervalued right now?

At $5.63, 1 of 2 active models suggest AMIX may be undervalued, while 1 indicate potential overvaluation. The median of all 2 fair value estimates is $7.10, 26.1% above the current price of $5.63 — a consensus view that AMIX is undervalued. The assessment depends on which methodology best fits Autonomix Medical, Inc.'s business model in Medical Devices.

What does a Quality of Company score of 4.2 mean for AMIX?

Autonomix Medical, Inc.'s QOC of 4.2/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on AMIX?

CirclFi analyzes AMIX with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 2 of 13 are active for this stock. Read the full methodology →

Is AMIX a value trap in 2026?

Autonomix Medical, Inc.'s Value Trap score is 53/100 (WARN). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 2-model valuation engine, Autonomix Medical, Inc. (AMIX) has a median fair value of $7.10 — 26.1% above the current price of $5.63 — as of 2026-08-27.” Source: circlfi.com/stock/AMIX/ · Methodology
Primary sources for this AMIX valuation
  • Financial statements: Autonomix Medical, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001617867) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for AMIX as of ; valuations recomputed .